Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
The National Pharmaceuticals Pricing Authority (NPPA) had last year identified brands including Dolo, Saridon Fabiflu, Ecosprin, Limcee, Sumo, Calpol, Corex syrup, Unwanted 72 and Thyronorm. They were shortlisted on the basis of their moving annual turnover value as per data from market research firm Pharmatrac.
Nirma Group is likely to acquire an 82.84% stake in Glenmark Life Sciences in a deal worth INR 6,664 to INR 7,000 crore. The company has emerged as the sole bidder following the deadline last week, with the acquisition likely to be facilitated by healthcare subsidiary Aculife Healthcare.
Trade generics are branded medicines that are not promoted to physicians but are directly sold through retailers and distributors. In India, trade generics have a market share of 20% by volume and 5-6% by value, according to data and analytics firm IQVIA. The segment is growing around 14-15% per annum.
Sun Pharma expects high-single-digit growth in its consolidated topline in FY24, driven by strong performance in all business verticals, according to its MD Dilip Shanghvi. The company will focus on sustainable and profitable business growth, cost efficiency, supply chain continuity, and investment in IT for secure systems, business operations, and digital transformation.
The cancer mortality trend in India has decreased by 0.19 per cent annually among men but increased by 0.25 per cent among women, which translates to an increase of 0.02 per cent among the combined sexes, a recent study said. The striking findings were part of an analysis of mortality trends of 23 major cancers in the Indian population, which killed 12.85 million Indians between 2000 and 2019.
"It is safe to conclude, without any qualms, that the deaths of the 70 children below the age of five between July and October 2022 related to acute kidney injury (AKI) are a direct result of contaminated medicines found in four cough and cold syrups imported by Atlantic Pharmacy from Maiden Pharmaceuticals in India," the task force said in its report.
World Hepatitis Day takes places every year on July 28, bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. In 2023 the theme is 'We're not waiting.
Baring Private Equity Asia (BPEA) EQT has agreed to buy a 60% stake in Indira IVF, the largest provider of fertility services in India, for $1.1bn, with existing investor TA Associates set to sell its 47% holding. Indira IVF, which has facilitated 125,000 successful pregnancies to date, is valued at between $1bn and $1.2bn. The company posted revenue of INR12.5bn ($169m) in its latest financial year and completes about 40,000 in vitro fertilisation cycles per year, said a release. India's IVF industry is a potential $12bn market that is expanding at a 20% compound annual growth rate.
A press release from Eastman Exports said it will use the new investment for capital expenditure, strengthening backward integration and customer acquisition among others. The funds will also help the company expand its presence in the global apparel industry, especially at a time when other countries are facing a slowdown and to capture the overall "China Plus One Strategy" of divesting manufacturing away from a single country.
Akums Drugs and Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) for a triple combination diabetes medication. The drug combines Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 to provide better treatment without the need for multiple drugs.
Medanta, the hospital chain operated by Global Health, has partnered with GE HealthCare to launch the Medanta e-ICU, which aims to provide advanced tele-ICU services in India. The initiative will enable 24/7 staffed Medanta e-ICU command centres equipped with technology from GE HealthCare for remote patient monitoring, allowing early interventions that improve clinical outcomes.
GlaxoSmithKline Pharmaceuticals (GSK India) on Wednesday reported 13% year-on-year (YoY) jump of net profit to Rs 131 crore for the quarter ended June 2023 led by robust volumes, price hikes and recovery of its vaccine business. The said it maintained its gross margins despite the National List of Essential Medicines (NLEM) impact, while EBITDA margins declined 1% to 19.1% on account of new product launch investments led by Shingrix.
The government on Tuesday said that till July 17, ceiling prices have been fixed for 915 scheduled formulations. Out of the total, ceiling prices of 691 formulations have been fixed under the National List of Essential Medicines (NLEM) 2022 and 224 formulations under NLEM 2015, Union Minister of State for Chemicals and Fertilisers Bhagwanth Khuba said in a written reply to Rajya Sabha.
Rating agency ICRA said it expects the revenues of its sample set of 25 Indian pharmaceutical companies which account for 60% of the overall Indian pharmaceutical industry to grow by 7-9% in FY24.
India's pharmaceutical market contracted by 4.5% in June due to a fall in anti-infectives and respiratory drug sales as Covid cases decreased. According to an IQVIA report, the Moving Annual Turnover (MAT) growth for June fell to 10.6% from 11.3% in May. The highest growth therapies were anti-viral, antineoplast/immunomodulator, urology and vaccines. The report also shows a higher growth rate for the chronic segment than the acute segment. Sandeep Budhiraja of Max Healthcare noted that they are seeing a relatively mild flu season, which is occurring earlier than usual.
AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets. The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing.
Crisil has upgraded the credit rating outlook of Fortis Healthcare basis sustained improvement in the business risk profile of the company. It has upgraded the credit rating on long-term bank facilities for Fortis Healthcare Limited (FHL) to 'AA / Stable outlook' from the earlier 'AA- / Positive outlook', the company said in a release.
Apollo Hospitals plans to have a transplant programme in all its locations along with collaborations with hospitals outside its network, as it sees rising demand from within India and overseas.
Eswara Reddy along with Animesh Kumar (Assistant Drugs Inspector), Biocon Biologics' Associate Vice President L Praveen Kumar, and Synergy Network India Private Limited director Dinesh Dua, were arrested last year in the bribery case allegedly to waive the Phase 3 clinical trial of 'Insulin Aspart' injection, a product developed by the company to manage Type 1 and Type 2 diabetes. However, Biocon Biologics, a subsidiary of Kiran Mazumdar Shaw-led Biocon, denied the allegations of bribery.
Hair loss and thinning are common problems nowadays. Due to all these issues, an increasing number of women are resorting to natural methods to boost hair growth. Here we take a look at the best natural ingredients for long and strong hair.
The association has been asking for a separate chapter on medical devices under the law. "This was assured to us in 2016 and was in line with the Parliament committee recommendations considering the huge potential of the industry,"Nath said.
Global Health (Medanta) had, in its red herring prospectus, reported an attrition rate of 51% among nurses for FY22. IPO-bound Yatharth Hospital has reported an attrition of 74% for FY23 in its draft red herring prospectus. Thane-based Jupiter Hospital has reported an attrition of 32% for FY22 in its draft RHP. The attrition rates at hospitals are far higher for nurses compared with those of doctors and other professionals.
The US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for the delivery devices unit of Biocon Sdn Bhd, Malaysia, a subsidiary of Biocon Biologics.
